The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
NO donors and NO delivery methods for controlling biofilms in chronic lung infections
Abstract
Nitric oxide (NO), the highly reactive radical gas, provides an attractive strategy in the control of microbial infections. NO not only exhibits bactericidal effect at high concentrations but also prevents bacterial attachment and disperses biofilms at low, nontoxic concentrations, rendering bacteria less tolerant to antibiotic treatment. The endogenously generated NO by airway epithelium in healthy populations significantly contributes to the eradication of invading pathogens. However, this pathway is often compromised in patients suffering from chronic lung infections where biofilms dominate. Thus, exogenous supplementation of NO is suggested to improve the therapeutic outcomes of these infectious diseases. Compared to previous reviews focusing on the mechanism of NO-mediated biofilm inhibition, this review explores the applications of NO for inhibiting biofilms in chronic lung infections. It discusses how abnormal levels of NO in the airways contribute to chronic infections in cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and primary ciliary dyskinesia (PCD) patients and why exogenous NO can be a promising antibiofilm strategy in clinical settings, as well as current and potential in vivo NO delivery methods. Key points: •The relationship between abnormal NO levels and biofilm development in lungs •The antibiofilm property of NO and current applications in lungs •Potential NO delivery methods and research directions in the future
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinically, NO-based dispersal remains a practical adjunct. It can resensitize biofilm aggregates, and early trials and translational reviews outline guidance on donor selection, delivery methods, and endpoints [134,291,292].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [291]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biofilm Dispersal: Mechanisms, Clinical Implications, and Potential Therapeutic Uses
Kaplan, J. B. (2010) · Journal of Dental Research · doi:10.1177/0022034509359403 · Cited by 949
Maragos, C. M., Morley, D., Wink, D. A., Dunams, T. M., Saavedra, J. E., Hoffman, A., Bove, A. A., Isaac, L., Hrabie, J. A., & Keefer, L. K. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00115a013 · Cited by 722
Antimicrobial Tolerance in Biofilms
Stewart, P. S. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mb-0010-2014 · Cited by 450 · cited 1×
“If cells in biofilms are reverted to planktonic state, they are sensitive to antibiotics (For more details please see review articles from Stewart 2015 and Ciofu and TolkerNielsen 2019).”
BackgroundEssential genome of Pseudomonas aeruginosa in cystic fibrosis sputum
Turner, K. H., Wessel, A. K., Palmer, G. C., Murray, J. L., & Whiteley, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419677112 · Cited by 432
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis
Zahoor, A., Sharma, S., & Khuller, G. K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.07.012 · Cited by 314
Sydow, K., Daiber, A., Oelze, M., Chen, Z., August, M., Wendt, M., Ullrich, V., Mülsch, A., Schulz, E., Keaney, J. F., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419267 · Cited by 300
Barraud, N., Storey, M. V., Moore, Z. P., Webb, J. S., Rice, S. A., & Kjelleberg, S. (2009) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2009.00098.x · Cited by 289
Nitric oxide–releasing macromolecular scaffolds for antibacterial applications
Yang, L., Feura, E. S., Ahonen, M. J. R., & Schoenfisch, M. H. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800155 · Cited by 218
Self-citationExhaled nitric oxide from lung periphery is increased in COPD
Brindicci, C., Ito, K., Resta, O., Pride, N. B., Barnes, P. J., & Kharitonov, S. A. (2005) · European Respiratory Journal · doi:10.1183/09031936.04.00125304 · Cited by 206
Genetics and biology of primary ciliary dyskinesia
Horani, A., Ferkol, T. W., Dutcher, S. K., & Brody, S. L. (2016) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2015.09.001 · Cited by 197
Research works printed but not linked: 251
- Abbas HA, Elsherbini AM, Shaldam MA (2019) Glyceryl trinitrate blocks staphyloxanthin and biofilm formation in Staphylococcus aureus. Afr Health Sci 19(1):1376–1384 · DOI
- Aguirre G, Boiani M, Cerecetto H, Fernández M, González M, León E, Pintos C, Raymondo S, Arredondo C, Pacheco JP, Basombrío MA (2006) Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies. Pharmazie. 61(1):54–59
- Ahmed MN, Porse A, Sommer MOA, Høiby N, Ciofu O (2018) Evolution of antibiotic resistance in biofilm and planktonic Pseudomonas aeruginosa populations exposed to subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 62(8):e00320–e00318 · DOI
- Ahonen MJR, Suchyta DJ, Zhu H, Schoenfisch MH (2018) Nitric oxide-releasing alginates. Biomacromolecules. 19(4):1189–1197. https://doi.org/10.1021/acs.biomac.8b00063 · DOI
- Ahonen MJR, Dorrier JM, Schoenfisch MH (2019a) Antibiofilm efficacy of nitric oxide-releasing alginates against cystic fibrosis bacterial pathogens. ACS Infect Dis 5(8):1327–1335 · DOI
- Ahonen MJR, Hill DB, Schoenfisch MH (2019b) Nitric oxide-releasing alginates as mucolytic agents. ACS Biomater Sci Eng 5(7):3409–3418 · DOI
- Alanin MC, Nielsen KG, von Buchwald C, Skov M, Aanaes K, Høiby N, Johansen HK (2015) A longitudinal study of lung bacterial pathogens in patients with primary ciliary dyskinesia. Clin Microbiol Infect 21(12):1093.e1–1093.e7 · DOI
- Allan RN, Morgan S, Brito-Mutunayagam S, Skipp AP, Feelisch M, Hayes SM, Hellier W, Clarke SC, Stoodley P, Burgess A, Ismail-Koch H, Salib RJ, Webb JS, Faust SN, Hall-Stoodley L (2016) Low concentrations of nitric oxide modulate Streptococcus pneumoniae biofilm metabolism and antibiotic tolerance. Antimicrob Agents Chemother 60(4):2456–2466 · DOI
- Al-Sa'doni H, Ferro A (2000) S-Nitrosothiols: a class of nitric oxide-donor drugs. Clin Sci (Lond) 98(5):507–520 · DOI · Paper page
- Annich GM, Meinhardt JP, Mowery KA, Ashton BA, Merz SI, Hirschl RB, Meyerhoff ME, Bartlett RH (2000) Reduced platelet activation and thrombosis in extracorporeal circuits coated with nitric oxide release polymers. Crit Care Med 28(4):915–920 · DOI
- Ansarin K, Chatkin JM, Ferreira IM, Gutierrez CA, Zamel N, Chapman KR (2001) Exhaled nitric oxide in chronic obstructive pulmonary disease: Relationship to pulmonary function. Eur Respir J 157(3 Pt 1):998–1002
- Arora DP, Hossain S, Xu Y, Boon EM (2015) Nitric oxide regulation of bacterial biofilms. Biochemistry 54(24):3717–3728 · DOI · Paper page
- Ashutosh K, Phadke K, Jackson JF, Steele D (2000) Use of nitric oxide inhalation in chronic obstructive pulmonary disease. Thorax. 55(2):109–113 · DOI
- Asmawi MZ, Moilanen E, Annala K, Rahkonen P, Kankaanranta H (1999) Effects of nitric oxide donors GEA 3162 and SIN-1 on ethanol-induced gastric ulceration in rats. Eur J Pharmacol 378(1):123–127 · DOI
- Azimi S, Roberts AEL, Peng S, Weitz JS, McNally A, Brown SP, Diggle SP (2020) Allelic polymorphism shapes community function in evolving Pseudomonas aeruginosa populations. ISME J 14:1929–1942 · DOI · Paper page
- Bandarage UK, Chen L, Fang X, Garvey DS, Glavin A, Janero DR, Letts LG, Mercer GJ, Saha JK, Schroeder JD, Shumway MJ, Tam SW (2000) Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J Med Chem 43(21):4005–4016 · DOI
- Barnes RJ, Bandi RR, Wong WS, Barraud N, McDougald D, Fane A, Kjelleberg S, Rice SA (2013) Optimal dosing regimen of nitric oxide donor compounds for the reduction of Pseudomonas aeruginosa biofilm and isolates from wastewater membranes. Biofouling. 29:203–212 · DOI
- Barnes RJ, Low JH, Bandi RR, Tay M, Chua F, Aung T, Fane AG, Kjelleberg S, Rice SA (2015) Nitric oxide treatment for the control of reverse osmosis membrane biofouling. Appl Environ Microbiol 81:2515–2524 · DOI
- Barraud N, Hassett DJ, Hwang S-H, Rice SA, Kjelleberg S, Webb JS (2006) Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 188:7344–7353 · DOI · Paper page
- Barraud N, Schleheck D, Klebensberger J, Webb JS, Hassett DJ, Rice SA, Kjelleberg S (2009a) Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J Bacteriol 191:7333–7342 · DOI · Paper page
- Barraud N, Kardak BG, Yepuri NR, Howlin RP, Webb JS, Faust SN, Kjelleberg S, Rice SA, Kelso MJ (2012) Cephalosporin-3’-diazeniumdiolates: targeted NO-donor prodrugs for dispersing bacterial biofilms. Angew Chem Int Ed 51:9057–9060 · DOI · Paper page
- Barraud N, Kelso MJ, Rice SA, Kjelleberg S (2015) Nitric oxide: a key mediator of biofilm dispersal with applications in infectious diseases. Curr Pharm Des 21(1):31–42 · DOI · Paper page
- Bartley BL, Gardner KJ, Spina S, Hurley BP, Campeau D, Berra L, Yonker LM, Carroll RW (2020) High-dose inhaled nitric oxide as adjunct therapy in cystic fibrosis targeting Burkholderia multivorans. Case Rep Pediatr 2020:1536714
- Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P (2012) Lung microbiology and exacerbations in COPD. Int J COPD 7:555–569
- Bertinaria M, Galli U, Sorba G, Fruttero R, Gasco A, Brenciaglia MI, Scaltrito MM, Dubini F (2003) Synthesis and anti-Helicobacter pylori properties of NO-donor/metronidazole hybrids and related compounds. Drug Dev Res 60:225–239 · DOI
- Bjarnsholt T (2013) The role of bacterial biofilms in chronic infections. APMIS. 136:1–51 · DOI · Paper page
- Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Høiby N (2009) Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 44:547–558 · DOI · Paper page
- Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sørensen SR, Moser C, Kühl M, Jensen PØ, Høiby N (2013) The in vivo biofilm. Trends Microbiol 21(9):466–474 · DOI · Paper page
- Boyton RJ, Openshaw PJ (2002) Pulmonary defences to acute respiratory infection. Br Med Bull 61(1):1–12 · DOI
- Brindicci C, Kharitonov SA, Ito M, Elliott MW, Hogg JC, Barnes PJ, Ito K (2010) Nitric oxide synthase isoenzyme expression and activity in peripheral lung tissue of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181(1):21–30 · DOI
- Brooks CD, Stewart AO, Basha A, Bhatia P, Ratajczyk JD, Martin JG, Craig RA, Kolasa T, Bouska JB, Lanni C (1995) (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. J Med Chem 38:4768–4775 · DOI
- Burney S, Caulfield JL, Niles JC, Wishnok JS, Tannenbaum SR (1999) The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat Res 424(1-2):37–49 · DOI · Paper page
- Cai YM, Webb JS (2020) Optimization of nitric oxide donors for investigating biofilm dispersal response in Pseudomonas aeruginosa clinical isolates. Appl Microbiol Biotechnol 104(20):8859–8869 · DOI
- Cairns S, Thomas JG, Hooper SJ, Wise MP, Frost PJ, Wilson MJ, Lewis MAO, Williams DW (2011) Molecular analysis of microbial communities in endotracheal tube biofilms. PLoS One 6(3):e14759 · DOI
- Carlson HK, Vance RE, Marletta MA (2010) H-NOX regulation of c-di-GMP metabolism and biofilm formation in Legionella pneumophila. Mol Microbiol 77:930–942 · DOI
- Chen C, Zhang E (2013) β-galactosyl-pyrrolidinyl diazeniumdiolate: an efficient tool to investigate nitric oxide functions on promoting cell death. Appl Microbiol Biotechnol 97:7377–7385 · doi:10.1007/s00253-013-5040-5
- Chen C, Shi YQ, Song J, Qi QS, Gu L, Wang PG (2006) Delivery of nitric oxide released from beta-Gal-NONOate activation by beta-galactosidase and its activity against Escherichia coli. Biol Pharm Bull 29(6):1239–1241 · DOI
- Chmiel JF, Davis PB (2003) State of the art: Why do the lungs of patients with cystic fibrosis become infected and why can’t they clear the infection? Respir Res 4(1):8 · DOI · Paper page
- Chung KH, Park SM, Baek IC, Jang J, Hong YW, Ahn SW (2016) Cyanide toxicity during cardiopulmonary bypass with small dose of nitroprusside—a case report. Korean J Anesthesiol 69(2):181–184 · doi:10.4097/kjae.2016.69.2.181
- Ciofu O, Tolker-Nielsen T (2019) Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents—how P. aeruginosa can escape antibiotics. Front Microbiol 10:913 · DOI · Paper page
- Clark ST, Guttman DS, Hwang DM (2018) Diversification of Pseudomonas aeruginosa within the cystic fibrosis lung and its effects on antibiotic resistance. FEMS Microbiol Lett 365(6) · DOI
- Clini E, Bianchi L, Pagani M, Ambrosino N (1998) Endogenous nitric oxide in patients with stable COPD: correlates with severity of disease. Thorax. 53(10):881–883 · DOI
- Collins SA, Kelso MJ, Rineh A, Yepuri NR, Coles J, Jackson CL, Halladay GD, Walker WT, Webb JS, Hall-Stoodley L, Connett GJ, Feelisch M, Faust SN, Lucas JSA, Allan RN (2017) Cephalosporin-3′-diazeniumdiolate NO donor prodrug PYRRO-C3D enhances azithromycin susceptibility of nontypeable Haemophilus influenzae biofilms. Antimicrob Agents Chemother 61(2):e02086–e02016 · DOI
- Corradi M, Majori M, Cacciani GC, Consigli GF, De’Munari E, Pesci A (1999) Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease. Thorax. 54(7):572–575 · DOI · Paper page
- Csoma Z, Bush A, Wilson NM, Donnelly L, Balint B, Barnes PJ, Kharitonov SA (2003) Nitric oxide metabolites are not reduced in exhaled breath condensate of patients with primary ciliary dyskinesia. Chest. 124(2):633–638 · DOI
- Cutruzzolà F, Frankenberg-Dinkel N (2016) Origin and impact of nitric oxide in Pseudomonas aeruginosa biofilms. J Bacteriol 198(1):55–65 · DOI · Paper page
- Daiber A, Münzel T (2015) Organic nitrate therapy, nitrate tolerance, and nitrate-induced endothelial dysfunction: emphasis on redox biology and oxidative stress. Antioxid Redox Signal 23(11):899–942 · DOI · Paper page
- Darling KE, Evans TJ (2003) Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis. Infect Immun 71:2341–2349 · DOI
- Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, Chang CT (1998) Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose–response multicenter study. The I-NO/PPHN Study Group. Pediatrics 101:325–334 · DOI · Paper page
- Davies DW, Kadar D, Steward DJ, Munro IR (1975) A sudden death associated with the use of sodium nitroprusside for induction of hypotension during anaesthesia. Can Anaesth Soc J 22(5):547–552 · doi:10.1007/bf03013407
- de Jesús Valle MJ, Dinis-Oliveira RJ, Carvalho F, Bastos ML, Sánchez Navarro A (2008) Toxicological evaluation of lactose and chitosan delivered by inhalation. J Biomater Sci Polym Ed 19(3):387–397 · DOI
- De Oliveira CPMS, Simplicio FI, De Lima VMR, Yuahasi K, Lopasso FP, Alves VAF, Abdalla DSP, Carrilho FJ, Laurindo FRM, De Oliveira MG (2006) Oral administration of S-nitroso-N-acretylcysteine prevents the onset of non alcoholic fatty liver disease in rats. World J Gastroenterol 12(12):1905–1911 · DOI
- de Souza PC, Fernandes GFS, Marino LB, Ribeiro CM, da Silva PB, Chorilli M, Silva CSP, Resende FA, Solcia MC, de Grandis RA, Costa CAS, Cho SH, Wang Y, Franzblau SG, dos Santos JL, Pavan FR (2020) Furoxan derivatives demonstrated in vivo efficacy by reducing Mycobacterium tuberculosis to undetectable levels in a mouse model of infection. Biomed Pharmacother 130:110592 · DOI
- den Uil CA, Brugts JJ (2015) Impact of intravenous nitroglycerin in the management of acute decompensated heart failure. Curr Heart Fail Rep 12(1):87–93 · doi:10.1007/s11897-014-0230-8
- Derelanko MJ, Gad SC, Powers WJ, Mulder S, Gavigan F, Babich PC (1985) Toxicity of cyclohexanone oxime: I. Hematotoxicity following subacute exposure in rats. Toxicol Sci 5(1):117–127 · doi:10.1093/toxsci/5.1.117
- Diaconu O, Siriopol I, Poloșanu LI, Grigoraș I (2018) Endotracheal tube biofilm and its impact on the pathogenesis of ventilator-associated pneumonia. J Crit Care Med 4(2):50–55 · DOI
- Dorken G, Ferguson GP, French CE, Poon WCK (2012) Aggregation by depletion attraction in cultures of bacteria producing exopolysaccharide. J R Soc Interface 9(77):3490–3502 · doi:10.1098/rsif.2012.0498
- dos Santos Fernandes GF, de Souza PC, Marino LB, Chegaev K, Guglielmo S, Lazzarato L, Fruttero R, Chung MC, Pavan FR, dos Santos JL (2016) Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis. Eur J Med Chem 123:523–531 · DOI
- Downey DG, Bell SC, Elborn JS (2009) Neutrophils in cystic fibrosis. Thorax. 397(6):485–496
- Duan J, Kasper DL (2011) Oxidative depolymerization of polysaccharides by reactive oxygen/nitrogen species. Glycobiology. 21(4):401–409 · DOI · Paper page
- Duong HTT, Adnan NNM, Barraud N, Basuki JS, Kutty SK, Jung K, Kumar N, Davis TP, Boyer C (2014a) Functional gold nanoparticles for the storage and controlled release of nitric oxide: applications in biofilm dispersal and intracellular delivery. J Mater Chem B 2:5003–5011 · DOI
- Duong-Quy S (2019) Clinical utility of the exhaled nitric oxide (NO) measurement with portable devices in the management of allergic airway inflammation and asthma. J Asthma Allergy 12:331–341 · DOI
- Eichholzer M, Gutzwiller F (1998) Dietary nitrates, nitrites, and N-nitroso compounds and cancer risk: a review of the epidemiologic evidence. Nutr Rev 56(4 Pt 1):95–105
- Elmedal B, Mulvany MJ, Simonsen U (2005) Dual impact of a nitric oxide donor, GEA 3175, in human pulmonary smooth muscle. Eur J Pharmacol 516(1):78–84 · doi:10.1016/j.ejphar.2005.04.017
- Elphick HE, Demoncheaux EA, Ritson S, Higenbottam TW, Everard ML (2001) Exhaled nitric oxide is reduced in infants with cystic fibrosis. Thorax 56:151–152 · DOI
- Feelisch M, Schönafingeri K, Noack H (1992) Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem Pharmacol 44(6):1149–1157 · DOI · Paper page
- Feit CG, Chug MK, Brisbois EJ (2019) Development of S-Nitroso- N-acetylpenicillamine impregnated medical grade polyvinyl chloride for antimicrobial medical device interfaces. ACS Appl Bio Mater 2(10):4335–4345 · DOI
- Fiorucci S, Antonelli E, Burgaud JL, Morelli A (2001) Nitric oxide-releasing NSAIDs: a review of their current status. Drug Saf 24(11):801–811 · DOI
- Fischer JT, Hossain S, Boon EM (2019) NosP modulates cyclic-di-gmp signaling in Legionella pneumophila. Biochemistry. 58(42):4325–4334 · DOI
- Flemming H-C, Wingender J (2010) The biofilm matrix. Nat Rev Microbiol 8:623–633 · DOI · Paper page
- Fliegauf M, Sonnen AFP, Kremer B, Henneke P (2013) Mucociliary clearance defects in a murine in vitro model of Pneumococcal airway infection. PLoS One 8(3):e59925 · DOI
- Fukada J, Schena S, Tack I, Ruiz P, Kurimoto Y, Pang M, Aitouche A, Abe T, Striker LJ, Pham SM (2000) FK409, a spontaneous nitric oxide releaser, attenuates allograft vasculopathy in a rat aortic transplant model. Circ Res 87(1):66–72 · doi:10.1161/01.res.87.1.66
- Fung C, Naughton S, Turnbull L, Tingpej P, Rose B, Arthur J, Hu H, Harmer C, Harbour C, Hassett DJ, Whitchurch CB, Manos J (2010) Gene expression of Pseudomonas aeruginosa in a mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum. J Med Microbiol 59(Pt 9):1089–1100 · DOI
- Ghigo D, Calvino R, Heller R, Calvino R, Alessio P, Fruttero R, Gasco A, Bosia A, Pescarmona G (1992) Characterization of a new compound, S35b, as a guanylate cyclase activator in human platelets. Biochem Pharmacol 43(6):1281–1288 · DOI
- Gifford AM, Chalmers JD (2014) The role of neutrophils in cystic fibrosis. Curr Opin Hematol 21(1):16–22 · DOI
- Gloag ES, German GK, Stoodley P (2018) Viscoelastic properties of Pseudomonas aeruginosa variant biofilms. Sci Rep 8:9691 · DOI
- Glover RE, Corbett JT, Burka LT, Mason RP (1999) In vivo production of nitric oxide after administration of cyclohexanone oxime. Chem Res Toxicol 12(10):952–957 · DOI
- Gordon Sahuquillo M, Geffner P, Aroca M, Villarreal Tello E, Ruiz Ramos J, Ruiz Orenga B, Sanchez Lopez M, Frasquet J, Gonzalez Barbera E, Castellanos Ortega A, Ramirez Galleymore P (2015) Impact of persistent endotracheal tube biofilm on ventilator-associated pneumonia clinical and microbiological response. Intensive Care Med Exp 3(Suppl 1):A700 · doi:10.1186/2197-425x-3-s1-a700
- Gotoh H, Kasaraneni N, Devineni N, Dallo SF, Weitao T (2010) SOS involvement in stress-inducible biofilm formation. Biofouling. 26(5):603–611 · DOI
- Grasemann H, Michler E, Wallot M, Ratjen F (1997) Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 24(3):173–177 · DOI · Paper page
- Grasemann H, Ioannidis I, Tomkiewicz RP, De Groot H, Rubin BK, Ratjen F (1998) Nitric oxide metabolites in cystic fibrosis lung disease. Arch Dis Child 78(1):49–53 · DOI
- Grasemann H, Gärtig SS, Wiesemann HG, Teschler H, Konietzko N, Ratjen F (1999) Effect of l-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome. Eur Respir J 13(1):114–118 · DOI
- Grasemann H, Knauer N, Buscher R, Hubner K, Drazen JM, Ratjen F (2000) Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am J Respir Crit Care Med 162:2172–2176 · DOI
- Grasemann H, Storm van’s Gravesande K, Gärtig S, Kirsch M, Büscher R, Drazen JM, Ratjen F (2002) Nasal nitric oxide levels in cystic fibrosis patients are associated with a neuronal NO synthase (NOS1) gene polymorphism. Nitric Oxide Biol Chem 6(2):236–241 · DOI
- Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FBJM, Erzurum SC (1995) Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc Natl Acad Sci U S A 92(17):7809–7813 · DOI · Paper page
- Hajian B, De Backer J, Vos W, Van Holsbeke C, Ferreira F, Quinn DA, Hufkens A, Claes R, de Backer W (2016) Pulmonary vascular effects of pulsed inhaled nitric oxide in COPD patients with pulmonary hypertension. Int J COPD 11:1533–1541 · DOI
- Hall JR, Maloney SE, Jin H, Taylor JB, Schoenfisch MH (2019) Nitric oxide diffusion through cystic fibrosis-relevant media and lung tissue. RSC Adv 9:40176–40183 · DOI
- Hall JR, Rouillard KR, Suchyta DJ, Brown MD, Ahonen MJR, Schoenfisc MH (2020) Mode of nitric oxide delivery affects antibacterial action. ACS Biomater Sci Eng 6(1):433–441 · DOI
- Hallman M, Bry K (1996) Nitric oxide and lung surfactant. Semin Perinatol 20(3):173–185 · DOI
- Hasan S, Albayaty YNS, Thierry B, Prestidge CA, Thomas N (2018) Mechanistic studies of the antibiofilm activity and synergy with antibiotics of isosorbide mononitrate. Eur J Pharm Sci 115:50–56 · DOI
- Hecker M, Vorhoff W, Bara AT, Mordvintcev PI, Busse R (1995) Characterization of furoxans as a new class of tolerance-resistant nitrovasodilators. Naunyn Schmiedeberg's Arch Pharmacol 351(4):426–432 · DOI
- Hetrick EM, Shin JH, Paul HS, Schoenfisch MH (2009) Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. Biomaterials. 30(14):2782–2789 · DOI · Paper page
- Hink U, Daiber A, Kayhan N, Kraatz C, Trischler J, Oelze M, Mollnau H, Wenzel P, Vahl C, Münzel T (2007) Oxidative inhibition of the mitochondrial aldehyde dehydrogenase (ALDH-2) promotes nitroglycerin tolerance in human blood vessels. Thorac Cardiovasc Surg 50(23):2226–2232
- Hoegger MJ, Fischer AJ, McMenimen JD, Ostedgaard LS, Tucker AJ, Awadalla MA, Moninger TO, Michalski AS, Hoffman EA, Zabner J, Stoltz DA, Welsh MJ (2014) Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science. 345(6198):818–822 · DOI · Paper page
- Hoffman LR, D’Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI (2005) Aminoglycoside antibiotics induce bacterial biofilm formation. Nature. 436(7054):1171–1175 · DOI · Paper page
- Högman M, Thornadtsson A, Bröms K, Janson C, Lisspers K, Ställberg B, Hedenström H, Malinovschi A (2019) Different relationships between FENO and COPD characteristics in smokers and ex-smokers. COPD J Chronic Obstr Pulm Dis 16(3-4):227–233 · DOI
- Hoiby N (1977) Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl 58(2):65–79
- Høiby N (2002) Understanding bacterial biofilms in patients with cystic fibrosis: Current and innovative approaches to potential therapies. J Cyst Fibros 1(4):249–254 · DOI
- Høiby N (2017) A short history of microbial biofilms and biofilm infections. APMIS. 125(4):272–275 · DOI · Paper page
- Horváth I, Loukides S, Wodehouse T, Csiszér E, Cole PJ, Kharitonov SA, Barnes PJ (2003) Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax. 58(1):68–72 · DOI
- Hottinger DG, Beebe DS, Kozhimannil T, Prielipp RC, Belani KG (2014) Sodium nitroprusside in 2014: a clinical concepts review. J Anaesthesiol Clin Pharmacol 30(4):462–471 · DOI · Paper page
- Howlin RP, Cathie K, Hall-stoodley L, Cornelius V, Duignan C, Allan RN, Fernandez BO, Barraud N, Bruce KD, Jefferies J, Kelso M, Kjelleberg S, Rice SA, Rogers GB, Pink S, Smith C, Sukhtankar PS, Salib R, Legg J, Carroll M, Daniels T, Feelisch M, Stoodley P, Clarke SC, Connett G, Faust SN, Webb JS (2017) Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Mol Ther 25:2104–2116 · DOI · Paper page
- Hoyt JC, Robbins RA, Habib M, Springall DR, Buttery LDK, Polak JM, Barnes PJ (2003) Cigarette smoke decreases inducible nitric oxide synthase in lung epithelial cells. Exp Lung Res 29(1):17–28 · DOI
- Hsu MF, Chen YS, Huang LJ, Tsao LT, Kuo SC, Wang JP (2006) GEA3162, a nitric oxide-releasing agent, activates non-store-operated Ca2+ entry and inhibits store-operated Ca2+ entry pathways in neutrophils through thiol oxidation. Eur J Pharmacol 535(1-3):43–52 · DOI
- Hunt BC, Stanford D, Xu X, Li J, Gaggar A, Rowe SM, Raju SV, Swords WE (2020) Haemophilus influenzae persists in biofilm communities in a smoke-exposed ferret model of COPD. ERJ Open Res 6(3):00200–02020
- Hynes G, Brightling C, Bafadhel M (2015) Fractional exhaled nitric oxide in chronic obstructive pulmonary disease. Eur Respir J 46:PA3993
- Islam M, Durie I, Ramadan R, Purchase D, Marvasi M (2020) Exploitation of nitric oxide donors to control bacterial adhesion on ready-to-eat vegetables and dispersal of pathogenic biofilm from polypropylene. J Sci Food Agric 100(7):3078–3086 · DOI
- Jansen A, Drazen JM, Osborne JA, Brown R, Loscalzo J, Stamler JS (1992) The relaxant properties in guinea pig airways of S-nitrosothiols. J Pharmacol Exp Ther 261(1):154–160
- Jardeleza C, Foreman A, Baker L, Paramasivan S, Field J, Tan LW, Wormald P-J (2011) The effects of nitric oxide on Staphylococcus aureus biofilm growth and its implications in chronic rhinosinusitis. Int Forum Allergy Rhinol 1:438–444 · DOI
- Jardeleza C, Rao S, Thierry B, Gajjar P, Vreugde S, Prestidge CA, Wormald PJ (2014) Liposome-encapsulated ISMN: a novel nitric oxide-based therapeutic agent against Staphylococcus aureus biofilms. PLoS One 9(3):e92117 · DOI
- Jean D, Maître B, Tankovic J, Meignan M, Adnot S, Brun-Buisson C, Harf A, Delclaux C (2002) Beneficial effects of nitric oxide inhalation on pulmonary bacterial clearance. Crit Care Med 30(2):442–447 · DOI
- Ji Y, Li G, Zhang W, Ma D, Xue W (2017) Cross-linked branched polyethylenimine used as a nitric oxide donor for prolonged nitric oxide release. Mater Sci Eng C 81(1):492–499 · DOI
- Jiang WT, Liu XS, Xu YJ, Ni W, Chen SX (2015) Expression of nitric oxide synthase isoenzyme in lung tissue of smokers with and without chronic obstructive pulmonary disease. Chin Med J 128(12):1584–1589 · DOI
- Jones KL, Hegab AH, Hillman BC, Simpson KL, Jinkins PA, Grisham MB, Owens MW, Sato E, Robbins RA (2000) Elevation of nitrotyrosine and nitrate concentrations in cystic fibrosis sputum. Pediatr Pulmonol 30(2):79–85 · doi:10.1002/1099-0496(200008)30:2<79::aid-ppul1>3.0.co;2-1
- Julián E, Baelo A, Gavaldà J, Torrents E (2015) Methyl-hydroxylamine as an efficacious antibacterial agent that targets the ribonucleotide reductase enzyme. PLoS One 10(3):e0122049 · DOI
- Kankaanranta H, Rydell E, Petersson AS, Holm P, Moilanen E, Corell T, Karup G, Vuorinen P, Pedersen SB, Wennmalm Å, Metsä-Ketelä T (1996) Nitric oxide-donating properties of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives. Br J Pharmacol 117(3):401–406 · DOI
- Karup G, Preikschat H, Wilhelmsen ES, Pedersen SB, Marcinkiewicz E, Cieslik K, Gryglewski RJ (1994) Mesoionic oxatriazole derivatives—a new group of NO-donors. Pol J Pharmacol 46(6):541–552
- Keen C, Gustafsson P, Lindblad A, Wennergren G, Olin AC (2010) Low levels of exhaled nitric oxide are associated with impaired lung function in cystic fibrosis. Pediatr Pulmonol 45(3):241–248 · DOI
- Kelly J (2017) Environmental scan of cystic fibrosis research worldwide. J Cyst Fibros 16(3):367–370 · doi:10.1016/j.jcf.2016.11.002
- Kido Y, Mitani A, Isago H, Takeshima H, Narumoto O, Tanaka G, Yamauchi Y, Takai D, Ohishi N, Nagase T (2017) Successful treatment of pulmonary injury after nitrogen oxide exposure with corticosteroid therapy: a case report and review of the literature. Respir Med Case Rep 20:107–110
- Kishikawa H, Ebberyd A, Römling U, Brauner A, Lüthje P, Lundberg JO, Weitzberg E (2013) Control of pathogen growth and biofilm formation using a urinary catheter that releases antimicrobial nitrogen oxides. Free Radic Biol Med 65:1257–1264 · DOI
- Kolpen M, Bjarnsholt T, Moser C, Hansen CR, Rickelt LF, Kühl M, Hempel C, Pressler T, Høiby N, Jensen PO (2014) Nitric oxide production by polymorphonuclear leucocytes in infected cystic fibrosis sputum consumes oxygen. Clin Exp Immunol 177(1):310–319 · DOI
- Korde Choudhari S, Chaudhary M, Bagde S, Gadbail AR, Joshi V (2013) Nitric oxide and cancer: a review. World J Surg Oncol 11:118 · DOI · Paper page
- Korten I, Liechti M, Singer F, Hafen G, Rochat I, Anagnostopoulou P, Müller-Suter D, Usemann J, Moeller A, Frey U, Latzin P, Casaulta C (2018) Lower exhaled nitric oxide in infants with cystic fibrosis compared to healthy controls. J Cyst Fibros 17(1):105–108 · DOI
- Kwon L, Rosendorff C (2018) Chapter 20 - The medical treatment of stable angina. in: de Lemos JA, Omland TBT - Chronic coronary artery disease (eds). ISBN 9780323428804. Elsevier. pp 280–302 · DOI
- Lane C, Knight D, Burgess S, Franklin P, Horak F, Legg J, Moeller A, Stick S (2004) Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath. Thorax. 59(9):757–760 · DOI · Paper page
- Laursen BE, Stankevicius E, Pilegaard H, Mulvany M, Simonsen U (2006) Potential protective properties of a stable, slow-releasing nitric oxide donor, GEA 3175, in the lung. Cardiovasc Drug Rev 24(3-4):247–260 · DOI
- Laval J, Ralhan A, Hartl D (2016) Neutrophils in cystic fibrosis. Biol Chem 397(6):485–496 · DOI
- Lee KY, Mooney DJ (2012) Alginate: properties and biomedical applications. Prog Polym Sci 37(1):106–126 · DOI · Paper page
- Lee J, Kwak D, Kim H, Kim J, Hlaing SP, Hasan N, Cao J, Yoo JW (2020) Nitric oxide-releasing S-nitrosoglutathione-conjugated poly(Lactic-co-glycolic acid) nanoparticles for the treatment of MRSA-infected cutaneous wounds. Pharmaceutics. 12(7):618 · DOI
- Leid JG (2009) Bacterial biofilms resist key host defenses. Microbe. 4(2):66–70
- Li XH, Lee JH (2017) Antibiofilm agents: a new perspective for antimicrobial strategy. J Microbiol 55:753–766 · DOI · Paper page
- Li Y, Heine S, Entian M, Sauer K, Frankenberg-Dinkel N (2013) NO-induced biofilm dispersion in Pseudomonas aeruginosa is mediated by an MHYT domain-coupled phosphodiesterase. J Bacteriol 195:3531–3542 · DOI · Paper page
- Li H, Song C, Liu D, Ai Q, Yu J (2015) Molecular analysis of biofilms on the surface of neonatal endotracheal tubes based on 16S rRNA PCR-DGGE and species-specific PCR. Int J Clin Exp Med 8(7):11075–11084
- Li B, Ming Y, Liu Y, Xing H, Fu R, Li Z, Ni R, Li L, Duan D, Xu J, Li C, Xiang M, Song H, Chen J (2020) Recent developments in pharmacological effect, mechanism and application prospect of diazeniumdiolates. Front Pharmacol 11:923 · DOI
- Liu N, Xu Y, Hossain S, Huang N, Coursolle D, Gralnick JA, Boon EM (2012) Nitric oxide regulation of cyclic di-GMP synthesis and hydrolysis in Shewanella woodyi. Biochemistry. 51:2087–2099 · DOI
- Liu S, Zheng H, Yu W, Ramakrishnan V, Shah S, Gonzalez LF, Singh I, Graffagnino C, Feng W (2020) Investigation of S-nitrosoglutathione in stroke: a systematic review and meta-analysis of literature in pre-clinical and clinical research. Exp Neurol 328:113262 · DOI
- López A, Martinson SA (2017) Respiratory system, mediastinum, and pleurae. in: Pathologic basis of veterinary disease expert consult. 471–560 · DOI
- Loukides S, Kharitonov S, Wodehouse T, Cole PJ, Barnes PJ (1998) Effect of arginine on mucociliary function in primary ciliary dyskinesia. Lancet. 352(9125):371–372
- Lu Z, Huang W, Wang L, Xu N, Ding Q, Cao C (2018) Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J COPD 13:2695–2705 · DOI
- Lucas JS, Walker WT (2013) Nasal nitric oxide is an important test in the diagnostic pathway for primary ciliary dyskinesia. Ann Am Thorac Soc 10(6):645–647 · DOI
- Lundberg JO (2005) Acute purulent sinusitis triggered by topical nasal nitric oxide synthase inhibition. Am J Respir Crit Care Med 172(4):512–513 · DOI
- Maestrelli P, Páska C, Saetta M, Turato G, Nowicki Y, Monti S, Formichi B, Miniati M, Fabbri LM (2003) Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients. Eur Respir J 21(6):971–976 · DOI
- Maitz MF (2015) Applications of synthetic polymers in clinical medicine. Biosurf Biotribol 1(3):161–176 · DOI · Paper page
- Major TA, Panmanee W, Mortensen JE, Gray LD, Hoglen N, Hassett DJ (2010) Sodium nitrite-mediated killing of the major cystic fibrosis pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia under anaerobic planktonic and biofilm conditions. Antimicrob Agents Chemother 54(11):4671–4677 · DOI · Paper page
- Malerba M, Radaeli A, Olivini A, Damiani G, Ragnoli B, Montuschi P, Ricciardolo FLM (2014) Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed Res Int 2014:271918 · DOI
- Malinovschi A, Janson C, Holmkvist T, Norbäck D, Meriläinen P, Högman M (2006) Effect of smoking on exhaled nitric oxide and flow-independent nitric oxide exchange parameters. Eur Respir J 28(2):339–345 · DOI
- Malo-Ranta U, Ylä-Herttuala S, Metsä-Ketelä T, Jaakkola O, Moilanen E, Vuorinen P, Nikkari T (1994) Nitric oxide donor GEA 3162 inhibits endothelial cell-mediated oxidation of low density lipoprotein. FEBS Lett 337(2):179–183 · DOI
- Mangalea MR, Plumley BA, Borlee BR (2017) Nitrate sensing and metabolism inhibit biofilm formation in the opportunistic pathogen Burkholderia pseudomallei by reducing the intracellular concentration of c-di-GMP. Front Microbiol 8:1353 · DOI
- Martorana PA, Kettenbach B, Bohn H, Schönafinger K, Henning R (1994) Antiischemic effects of pirsidomine, a new nitric oxide donor. Eur J Pharmacol 257(3):267–273 · doi:10.1016/0014-2999(94)90138-4
- Marvasi M, Chen C, Carrazana M, Durie IA, Teplitski M (2014) Systematic analysis of the ability of nitric oxide donors to dislodge biofilms formed by Salmonella enterica and Escherichia coli O157:H7. AMB Express 4:42 · DOI
- Marvasi M, Durie IA, Henríquez T, Satkute A, Matuszewska M, Prado RC (2016) Dispersal of human and plant pathogens biofilms via nitric oxide donors at 4 °C. AMB Express 6(1):49 · DOI
- Marvig RL, Johansen HK, Molin S, Jelsbak L (2013) Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. PLoS Genet 9(9):e1003741 · DOI · Paper page
- Matsui H, Wagner VE, Hill DB, Schwab UE, Rogers TD, Button B, Taylor RM, Superfine R, Rubinstein M, Iglewski BH, Boucher RC (2006) A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A 103(48):18131–18136 · DOI · Paper page
- Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ (1998) Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:998–1002 · DOI · Paper page
- Medana C, Di Stilo A, Visentin S, Fruttero R, Gasco A, Ghigo D, Bosia A (1999) NO donor and biological properties of different benzofuroxans. Pharm Res 16(6):956–960 · DOI
- Megson IL, Greig IR, Gray GA, Webb DJ, Butler AR (1997) Prolonged effect of a novel S-nitrosated glyco-amino acid in endothelium-denuded rat femoral arteries: potential as a slow release nitric oxide donor drug. Br J Pharmacol 122(8):1617–1624 · DOI
- Meng QH, Springall DR, Bishop AE, Morgan K, Evans TJ, Habib S, Gruenert DC, Gyi KM, Hodson ME, Yacoub MH, Polak JM (1998) Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 184(3):323–331 · DOI · Paper page
- Mfuh AM, Larionov OV (2015) Heterocyclic N-oxides—an emerging class of therapeutic agents. Curr Med Chem 22(24):2819–2857 · DOI · Paper page
- Miller MR, Megson IL (2007) Recent developments in nitric oxide donor drugs. British Journal of Pharmacology 151:305–321 · DOI · Paper page
- Miller MR, Roseberry MJ, Mazzei FA, Butler AR, Webb DJ, Megson IL (2000) Novel S-nitrosothiols do not engender vascular tolerance and remain effective in glyceryltrinitrate-tolerant rat femoral arteries. Eur J Pharmacol 403(1-2):111–119 · DOI
- Miret-Casals L, Baelo A, Julián E, Astola J, Lobo-Ruiz A, Albericio F, Torrents E (2018) Hydroxylamine derivatives as a new paradigm in the search of antibacterial agents. ACS Omega 3(12):17057–17069 · doi:10.1021/acsomega.8b01384
- Miskoff JA, Dewan A, Chaudhri M (2019) Fractional exhaled nitric oxide testing: Diagnostic utility in asthma, chronic obstructive pulmonary disease, or asthma-chronic obstructive pulmonary disease overlap syndrome. Cureus. 11(6):e4864
- Mocca B, Yin D, Gao Y, Wang W (2015) Moraxella catarrhalis-produced nitric oxide has dual roles in pathogenicity and clearance of infection in bacterial-host cell co-cultures. Nitric Oxide Biol Chem 51:52–62 · DOI
- Morgan R, Kohn S, Hwang S-H, Hassett DJ, Sauer K (2006) BdlA, a chemotaxis regulator essential for biofilm dispersion in Pseudomonas aeruginosa. J Bacteriol 188:7335–7343 · DOI · Paper page
- Mowery KA, Schoenfisch MH, Saavedra JE, Keefer LK, Meyerhoff ME (2000) Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release. Biomaterials. 21(1):9–21 · DOI · Paper page
- Mu L, Feng SS, Go ML (2000) Study of synthesis and cardiovascular activity of some furoxan derivatives as potential NO-donors. Chem Pharm Bull 48(6):808–816 · DOI
- Murakami S, Bacha EA, Mazmanian GM, Detruit H, Chapelier A, Dartevelle P, Herve P (1997) Effects of various timings and concentrations of inhaled nitric oxide in lung ischemia-reperfusion. The Paris-Sud University Lung Transplantation Group. Am J Respir Crit Care Med 156(2 Pt 1):454–458 · DOI
- Murrell W (1879) Nitro-glycerine as a remedy for angina pectoris. Lancet. 18(5):370–371
- Namivandi-Zangeneh R, Sadrearhami Z, Bagheri A, Sauvage-Nguyen M, Ho KKK, Kumar N, Wong EHH, Boyer C (2018) Nitric oxide-loaded antimicrobial polymer for the synergistic eradication of bacterial biofilm. ACS Macro Lett 7(5):592–597 · DOI
- Nelin LD, Potenziano JL (2019) Inhaled nitric oxide for neonates with persistent pulmonary hypertension of the newborn in the CINRGI study: time to treatment response. BMC Pediatr 19(1):17 · doi:10.1186/s12887-018-1368-4
- Nguyen TK, Selvanayagam R, Ho KKK, Chen R, Kutty SK, Rice SA, Kumar N, Barraud N, Duong HTT, Boyer C (2016) Co-delivery of nitric oxide and antibiotic using polymeric nanoparticles. Chem Sci 7(2):1016–1027 · DOI · Paper page
- Nyolczas N, Dékány M, Muk B, Szabó B (2018) Combination of hydralazine and isosorbide-dinitrate in the treatment of patients with heart failure with reduced ejection fraction. Adv Exp Med Biol 1067:31–45 · DOI
- Oh HS, Constancias F, Ramasamy C, Tang PYP, Yee MO, Fane AG, McDougald D, Rice SA (2018) Biofouling control in reverse osmosis by nitric oxide treatment and its impact on the bacterial community. J Membr Sci 550(15):313–321
- Paricio L, Neufeld B, Reynolds M (2019) Combined influence of nitric oxide and surface roughness in biofilm reduction across bacteria strains. Biointerphases. 14(2):021004 · DOI
- Patel RP, Yuan S, Kevil CG (2017) Chapter 4 - S-Nitrosothiols and nitric oxide biology, Nitric oxide (3rd edition), Academic Press, pp 45-56, · DOI
- Petrova OE, Sauer K (2012a) Dispersion by Pseudomonas aeruginosa requires an unusual posttranslational modification of BdlA. Proc Natl Acad Sci 109:16690–16695 · DOI · Paper page
- Petrova OE, Sauer K (2012b) PAS domain residues and prosthetic group involved in bdladependent dispersion response by Pseudomonas aeruginosa biofilms. J Bacteriol 194:5817–5828 · DOI
- Pifferi M, Bush A, Maggi F, Michelucci A, Ricci V, Conidi ME, Cangiotti AM, Bodini A, Simi P, Macchia P, Bonere AL (2011) Nasal nitric oxide and nitric oxide synthase expression in primary ciliary dyskinesia. Eur Respir J 37(3):572–577 · DOI
- Plate L, Marletta MA (2012) Nitric oxide modulates bacterial biofilm formation through a multicomponent cyclic-di-GMP signaling network. Mol Cell 46:449–460 · DOI · Paper page
- Poh WH, Barraud N, Guglielmo S, Lazzarato L, Rolando B, Fruttero R, Rice SA (2017) Furoxan nitric oxide donors disperse Pseudomonas aeruginosa biofilms, accelerate growth, and repress pyoverdine production. ACS Chem Biol 12(8):2097–2106 · DOI
- Privett BJ, Deupree SM, Backlund CJ, Rao KS, Johnson CB, Coneski PN, Schoenfisch MH (2010) Synergy of nitric oxide and silver sulfadiazine against gram-negative, gram-positive, and antibiotic-resistant pathogens. Mol Pharm 7:2289–2296 · DOI
- Quaderi SA, Hurst JR (2018) The unmet global burden of COPD. Glob Heal Epidemiol Genomics 3:e4 · DOI · Paper page
- Reid JJ (2001) ABT-761 (Abbott). Curr Opin Investig Drugs 2(1):68–71
- Reighard KP, Hill DB, Dixon GA, Worley BV, Schoenfisch MH (2015) Disruption and eradication of Pseudomonas aeruginosa biofilms using nitric oxide-releasing chitosan oligosaccharides. Biofouling. 31(9-10):775–787 · DOI · Paper page
- Reighard KP, Ehre C, Rushton ZL, Ahonen MJR, Hill DB, Schoenfisch MH (2017) Role of nitric oxide-releasing chitosan oligosaccharides on mucus viscoelasticity. ACS Biomater Sci Eng 3(6):1017–1026 · DOI
- Ren H, Wu J, Colletta A, Meyerhoff ME, Xi C (2016) Efficient eradication of mature Pseudomonas aeruginosa biofilm via controlled delivery of nitric oxide combined with antimicrobial peptide and antibiotics. Front Microbiol 7:1260
- Ricciardolo FLM (2003) Multiple roles of nitric oxide in the airways. Thorax. 58(2):175–182 · DOI · Paper page
- Richardson G, Benjamin N (2002) Potential therapeutic uses for S-nitrosothiols. Clin Sci (Lond) 102(1):99–105 · doi:10.1042/cs20010207
- Rindone JP, Sloane EP (1992) Cyanide toxicity from sodium nitroprusside: Risks and management. Ann Pharmacother 26:515–519 · DOI
- Rogers DF (2005) Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther 18(1):1–8 · DOI
- Römling U, Galperin MY, Gomelsky M (2013) Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. Microbiol Mol Biol Rev 77:1–52 · DOI · Paper page
- Rong F, Tang Y, Wang T, Feng T, Song J, Li P, Huang W (2019) Nitric oxide-releasing polymeric materials for antimicrobial applications: a review. Antioxidants. 8(11):556 · DOI · Paper page
- Rouillard KR, Hill DB, Schoenfisch MH (2020a) Antibiofilm and mucolytic action of nitric oxide delivered via gas or macromolecular donor using in vitro and ex vivo models. J Cyst Fibros 19(6):1004–1010 · DOI
- Rouillard KR, Markovetz MR, Bacudio LG, Hill DB, Schoenfisch MH (2020b) Pseudomonas aeruginosa biofilm eradication via nitric oxide-releasing cyclodextrins. ACS Infect Dis 6(7):1940–1950 · DOI
- Rouillard KR, Novak OP, Pistiolis AM, Yang L, Ahonen MJR, Mcdonald RA, Schoenfisch MH (2020c) Exogenous nitric oxide improves antibiotic susceptibility in resistant bacteria. ACS Infect Dis 7(1):23–33 · DOI
- Rozenbaum RT, van der Mei HC, Woudstra W, de Jong ED, Busscher HJ, Sharma PK (2019) Role of viscoelasticity in bacterial killing by antimicrobials in differently grown Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 63(4):e01972–e01918 · DOI
- Rutgers SR, Van Der Mark TW, Coers W, Moshage H, Timens W, Kauffman HF, Koëter GH, Postma DS (1999) Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax. 54(7):576–580 · DOI
- Sadrearhami Z, Shafiee FN, Ho KKK, Kumar N, Krasowska M, Blencowe A, Wong EHH, Boyer C (2019) Antibiofilm nitric oxide-releasing polydopamine coatings. ACS Appl Mater Interfaces 11(7):7320–7329 · DOI
- Sáenz De Tejada I, Garvey DS, Schroeder JD, Shelekhin T, Letts LG, Fernández A, Cuevas B, Gabancho S, Martínez V, Angulo J, Trocha M, Marek P, Cuevas P, Tam SW (1999) Design and evaluation of nitrosylated α-adrenergic receptor antagonists as potential agents for the treatment of impotence. J Pharmacol Exp Ther 290(1):121–128
200 of 251 shown
Cited by
Elbehiry, A., Marzouk, E., Edrees, H. M., Ibrahem, M., Alzahrani, S., Anagreyyah, S., Abualola, H., Alghamdi, A., Alzahrani, A., Jaber, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14010109 · Cited by 34
Metadata
- Authors
- Cai, Y.-M., Zhang, Y.-D., & Yang, L.
- ORCID
- Cai, Yu-Ming
- Venue
- Applied Microbiology and Biotechnology
- Published
- 2021-05
- Volume
- 105
- Issue
- 10
- Pages
- 3931-3954
- ISSN
- 0175-7598
- 1432-0614
- Cited by
- 25
- References
- 13
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 2 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NO donors and NO delivery methods for controlling biofilms in chronic lung infections. https://app.cochat.ai/papers/10.1007/s00253-021-11274-2
- The paper
- Cai, Y.-M., Zhang, Y.-D., & Yang, L. (2021). NO donors and NO delivery methods for controlling biofilms in chronic lung infections. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-021-11274-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.